AnCan has long been perplexed by the prostate cancer category “non-metastatic Castrate Resistant” or even “non-metastatic Hormone Sensitive”. If PSA is rising after primary treatment but prior to hormone treatment, something’s going on, however, ‘micro-metastatic’. It’s like being just a little bit pregnant!!
This paper considers a new category, PSMA Positive Biochemically Recurrent – PSMA+ BCR. We circulated the paper to our Brains Trust and reached out to Dr. Ravi Madan at the National Cancer Institute (NCI) with a couple of questions. Dr Madan offered to meet with us along with his colleague, Dr. Melissa Abel. What resulted was this REMARKABLE video that could present many of our recurrent and advanced AnCan (& non-AnCan) participants with one of the most mind-blowing videos many have seen in a long time,
DO YOU REALLY NEED TREATMENT??
As the venerable and highly respected Dr. Paul Schellhammer said in the meeting, “it’s like listening 15 years ago to the folks who began to promote active surveillance ( in first line treatment)” Dr. Madan and Dr. Abel have collected solid data from around 150 patients that suggests men with slow PSA doubling times can “play the long game” as Dr. Ravi calls it, and defer active treatment when their disease recurs.
PLEASE watch this astonishing presentation, listen to some excellent observations and questions, and consider how it relates to your own situation. And spread the word to others. Dr. Madan’s and Dr. Abel’s NCI clinical trial can be found at https://www.clinicaltrials.gov/study/NCT05588128. Don’t immediately assume you’re not eligible before speaking with them… but you’ll have to watch the video to get their contact information.
Hi-Risk/Recurrent/Advanced PrCa Video Chat, 1/19/26
AnCan is closing out its Annual Fundraising Campaign. If you haven’t donated yet, consider the priceless value we bring . Please donate – especially if you watch our recordings and are not on our Mailchimp list. https://ancan.org/donate/
AnCan thanks the following sponsors for making this recording possible: Novartis, Johnson and Johnson, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: After 15 years, Prostate cancer recurs for one Gent; and the 2nd time, 13 years later, for another.
Topics Discussed
Newbie needs to switch to a GU MO; PrCa metastasizes after 15 yrs; singlet to doublet during RT; Pluvicto failing after 10x sessions – STEAP1 xaluritamig (AMG509 ) next but heads up!; early signs of 2nd recurrence; Eligard vs Firmagon (agonist vs antagonist LHRH); first GU med onc appointment coming up; managing hot flashes; Oxybutynin again; doc can’t get approval right so switches drug; PSMA shows Nodes may not need RT; abiraterone dosing;
Chat
Rick Davis sent: 6:10 PM
PLEASE – no mention of the Championship Game tonight. Some peeps are recording it.
Need to leave – pass my bedtime. Catch you all next week!
Bob Schwartz U.S.N. Venice, FL. sent: 7:03 PM
Another GOOD Mtg., have to go, see everyone next week.
Rick Davis sent: 7:26 PM
Xaluritamig (AMG 509) is a novel bispecific T-cell engager (TCE) immunotherapy
Bob Y — Los Angeles sent: 7:27 PM
Appreciate everyone. I, too, have to go. See you next week.
Len sent: 7:30 PM
STEAP1 (Six-Transmembrane Epithelial Antigen of the Prostate 1) is detected in prostate cancer (PCa) primarily through tissue analysis (immunohistochemistry), showing overexpression in malignant cells, and via liquid biopsies (extracellular vesicles in plasma), using methods like nanoscale flow cytometry,
AnCan–John A sent: 7:31 PM
thanks Len
Frank Ciambra sent: 7:32 PM
thank you
Rick Davis sent: 7:32 PM
Doubling time very unreliable at such low levels, Neil
dan-s sent: 7:40 PM
I also have to scoot… thanks all.
Barbara and Joe sent: 7:54 PM
are you saying lupron?
Jim Marshall, Veteran, Alexandria, VA sent: 7:55 PM
Lupron & Eligard are the exact same drug. Jim
Rick Davis sent: 7:56 PM
Are you asking about the Depot shots?
Rick Davis sent: 7:57 PM
Oxybutynin…. good for hot flashes if you are on abi
Steve L sent: 7:57 PM
Must leave at 7, Best to all.
Alain sent: 7:58 PM
See you next time guys!
Barbara and Joe sent: 7:58 PM
I was asking about a two tier therapy
Steve Lsent: 7:59 PM
no , thank you.
Alfredo in Houston, TX sent: 8:00 PM
I must disconnect shortly. Thanks to everyone; I learn something new from every session.
Rick Davis sent: 8:01 PM
ADT + ARSI = doublet. ADT can be one of several drugs.
Thomas Matica sent: 8:02 PM
Signing out. Thanks to everyone. Peace.
Len sent: 8:02 PM
Dan – Trade name for oxybutynin is Ditropan.
Barry Blomquist sent: 8:06 PM
Thanks guys!
Richard B, Silver Spring, MD sent: 8:09 PM
As much as I would like to remain I need to bow out for the evening. I can save my question until next session. Always appreciate the information on these meeting. Good night!
NEW monthy GAY & BISEXUAL MEN’S Prostate Cancer Group starting Tue, Oct 21, 5.30 pm Eastern.
Sign up at https://ancan.org/contact-us/
AnCan thanks the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Myriad Genetics, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Bust your blinded trial by testing your own testosterone..
Topics Discussed
Doublet provides enduring success; 3+4 reveals bladder neck spread; Decipher used for determining length of HT; Spot RT flare…bust trial blinding by testing your T; blood tests get into the weeds of hormone activity; Embr works; testostrone fluctuates.
AnCan – rick 6:36 PM Dr. Alan Bryce, City of Hope, PX https://www.cityofhope.org/alan-bryce https://embrlabs.com/products/embr-wave-2?variant=39271596032118
AnCan – rick 7:06 PM via John Maxwell I use the EmberWave and it works well a night. However, you should give it 30-days of consistent use to notice the full benefit.
Michael Wolf 7:26 PM This is Michael Wolf, I yield back today and will be back with an update and questions for the next meeting. Its my wifes birthday and we cant be late for our dinner reservations. Thanks!
Jay Mills 7:32 PM Rick, I need to sign off. My questions can wait. Enjoyed the group tonight. Thanks to all.
Steve, North Michigan 7:35 PM I too am signing out for the night. Great Meeting!
Ed L 7:58 PM Good night all thanks for all the great info. Julian – Houston 7:58 PM Thank you for the great discussion!
Bruce Schrimpf 7:59 PM Nice meeting guys! Hopefully see you next time! BDS
Alfredo in Wimberley 8:02 PM Stay positive everyone. Thank you.
Gay or bisexual men diagnosed with prostate cancer have particular concerns. Addressing them with your peers is far easier!
AnCan Foundation, the innovator of virtual support groups, addresses special interests in special groups. We gather peers who easily relate and can support each other. Moderated by Gay & Bisexual peers with prostate cancer, this group addresses your specific questions. Our moderators are both technically expert and supportive. The group is open to all levels of prostate cancer, no matter where you are in your journey. AnCan offers specific prostate cancer groups at all levels. This group will focus on gay and bisexual issues less comfortable to raise in open groups rather than treatment questions.
This is a make-up meeting; moving forward, meetings will be on the 2nd Tuesdays of every month at 5:30 pm Eastern/4:30 pm Central/3:30 pm Mountain/2:30 pm Pacific, always in the AnCan Schmier Room.
Meetings are free and drop-in – no sign-up or pre-registration required. Sign up to receive a Reminder before each meeting at https://ancan.org/contact-us/. Other virtual AnCan Groups include stage-based prostate cancer, art and creative writing classes, Veterans programs, and mental health support.
AnCan Foundation dedicates this group in loving memory of Ken Mason
CNTV’s recent video features an interview with AnCan founder, Rick Davis. He explains that he started AnCan after his own diagnosis in 2007, after realizing inadequate support options, especially for those in remote areas. AnCan aims to eliminate barriers to entry for its various support groups, which range from cancer to chronic diseases. AnCan empowers patients to “Be your own best advocate” by providing them with the knowledge to speak confidently with their healthcare providers and offering peer-to-peer support.
